Lipella Pharmaceuticals Inc.
February 11, 2025 - by Joey Ramson
$LIPO is leading the Prism MarketView Pharmaceuticals index after gaining FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus (OLP), a condition affecting around 6 million Americans with no current FDA-approved therapies.
